Table 3 Details of the 15 patients with sacral giant cell tumors
From: Intralesional nerve-sparing surgery versus non-surgical treatment for giant cell tumor of the sacrum
Case | Age (years) | Sex | Tumor volume (cm3) | Tumor level | Involvement of the sacro-iliac joint | Involvement of the vascular or other organ system | Location | Preoperative treatment | Surgical approach | Local adjuvant therapy | Local recurrence or tumor progression | Treatment for local recurrence |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nerve-sparing surgery group | ||||||||||||
1 | 35 | F | 91 | S2-S4 | Yes | None | Eccentric | Denosumab (pre-op: 10 cycles and post-op: every 3 months) | Posterior | None | Yes (3 years after surgery) | Embolization and curettage |
2 | 36 | F | 14 | S2-S3 | No | None | Eccentric | None | Posterior | Phenol | Yes (52 months after surgery) | Denosumab (monthly for 10 months) |
3 | 48 | F | 75 | S1-S2 | Yes | None | Eccentric | Embolization and zoledronate (2 cycles) | Posterior | Phenol | Yes (53 months after surgery) | Denosumab (monthly for a year) and curettage |
4 | 16 | F | 14 | S1-S3 | Yes | Involvement of sacral plexus | Eccentric | Embolization | Posterior | Phenol | No | NA |
5 | 30 | F | 80 | S1-S2 | No | None | Eccentric | Denosumab (10 cycles) | Posterior | Phenol | No | NA |
6 | 43 | M | 295 | S3-S5 | No | Rectum compression | Central | None | Posterior | None | No | NA |
7 | 15 | M | 62 | S1-S2 | Yes | None | Eccentric | Embolization (three times) and zoledronate (one cycle) | Posterior | Phenol | No | NA |
8 | 15 | F | 132 | S1-S4 | No | Rectum and uterus compression | Central | Denosumab (pre-op: 10 cycles and post-op: 6 cycles) | Anterior/ posterior | None | Yes (14 months after surgery) | Denosumab (every 6 months for 5 years and 10 months) |
9 | 19 | F | 235 | S1-S3 | Yes | Rectum compression | Eccentric | Embolization and zoledronate (pre-op: 6 cycles and post-op: 6 cycles) | Anterior/ posterior | Phenol | No | NA |
Non-surgical treatment group | Duration and interval of the denosumab administration | |||||||||||
10 | 14 | F | 99 | S1-S3 | No | Uterus compression | Central | NA | NA | NA | No | Monthly for 5 years and bimonthly for 2 years |
11 | 32 | M | 230 | S2-S5 | No | None | Central | NA | NA | NA | No | Monthly for 3 years and every 3 months for 4 months |
12 | 66 | F | 678 | S1-S4 | No | None | Central | NA | NA | NA | No | Monthly for 3 years and every 3 months for 4 years |
13 | 65 | F | 146 | S1-S4 | No | None | Central | NA | NA | NA | No | Monthly for 3 years and every 3 months for 27 months |
14 | 31 | M | 252 | S1-S2 | No | None | Central | NA | NA | NA | No | Monthly for a year and then bimonthly for 4 months |
15 | 29 | F | 226 | S1-S4 | No | None | Eccentric | NA | NA | NA | No | Monthly for a year |